For decades, Congress has passed legislation to protect Americans from public health emergencies, ranging from national security threats to disease outbreaks and natural disasters, […]
A national security priority: BIO pushes PAHPA reauthorization in 2026 Read More »
There was bipartisan support for the PASTEUR Act’s approach to addressing AMR and for NSCEB recommendations, both BIO priorities. A bipartisan Senate hearing sought
Senators seek solutions for AMR, maintaining US biotech leadership Read More »
Industry and government leaders at BIO 2026 said stronger biotechnology policy, regulatory modernization, and public-private partnerships are essential to maintaining U.S. leadership in biotech
BIO 2026: American biotech leadership protects patients and national security Read More »
Industry, academic, and policy leaders at BIO 2026 discussed how federal research funding, private investment, and public-private partnerships can strengthen the U.S. biopharma ecosystem
For decades, the United States has led the world in developing new medicines, turning scientific breakthroughs into treatments that save and improve lives. But
As policy ecosystem threatens biotech, new treatments could drop by over 50% in 20 years Read More »
When a biotech firm sells investors on the promise of a new drug, what they are really selling is the intellectual property behind their
BIO is expanding its work to defend IP Read More »
Ensuring a brighter future for U.S. biotech requires modernizing the Food and Drug Administration (FDA) and addressing challenges from China, according to Kelly Seagraves,
BIO expert: Future of biotech depends on competing with China, updating FDA Read More »
A year after a congressional commission urged strategic action to prevent China from replacing America as the world leader in biotechnology, we still have
BIO CEO hails congressional report on threat of China dominating biotech Read More »
China gains a huge advantage in biotech competition by speeding up clinical trials, and America must respond, a member of the Board of the
BIO Board member advises Congress on China’s clinical trial competition Read More »
The threat to America’s leadership in biotech is a threat to our national security that we need to address now, two members of a
Biotech and national security: ‘Time to act but no time to wait’ Read More »
